SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalGMED - GenoMed Inc.


Previous 10 Next 10 
From: Tadsamillionaire9/20/2006 5:46:03 PM
   of 347
 
A severe bird flu pandemic among humans could cost the global economy up to $2 trillion, the World Bank said on Sunday, sharply raising earlier estimates.

The comments came as a senior World Health Organization official said the threat from the H5N1 avian flu virus was just as real today as it was six months ago, even if the headlines were not as scary.

Jim Adams, vice-president for East Asia and the Pacific and head of the Bank's avian flu taskforce, said a severe pandemic could cost more than three percent of the global economy's gross national product.

"We estimate this could cost certainly over $1 trillion and perhaps as high as $2 trillion in a worst-case scenario. So the threat, the economic threat, remains real and substantial," he told reporters at the annual IMF-World Bank meetings in Singapore.
timesofindia.indiatimes.com

Share RecommendKeepReplyMark as Last Read


From: Tadsamillionaire9/29/2006 4:58:01 PM
   of 347
 
Bird flu deaths hit 52 after man dies in Bandung

Yuli Tri Suwarni, The Jakarta Post, Bandung

A 20-year-old man hospitalized here over the past week for infection with the deadly bird flu virus died Thursday, raising the nationwide death toll to 52, or roughly a third of the total deaths worldwide.

"The virus crushed his lungs and caused the creation of progressive pneumonia which led to breathing problems," Cissy Rachiana Prawira, director of Hasan Sadikin Hospital, said.

The government confirmed the 20-year-old was positive for H5N1 earlier this week. The man's 23-year-old brother died with bird flu symptoms on Sunday just before being admitted to the hospital.

A third sibling, a 15-year-old female, is currently being treated at the same hospital even though she has been declared negative for the virus.

The younger brother was in critical condition since his admittance to the hospital Sunday from Santo Yusuf hospital in Bandung. Although he showed signs of improvement after he was put on a ventilator and administered high doses of Tamiflu, he remained in an unstable condition.



Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Tadsamillionaire who wrote (314)9/29/2006 4:58:48 PM
From: Tadsamillionaire
   of 347
 
GenoMed: Cure for Sickle Cell Pain
ST. LOUIS, Sept. 11 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), the Next Generation Disease Management company whose business is public health(TM), announced today that it has submitted a case report of a sickle cell patient whose pain disappeared with GenoMed's treatment approach, only to recur when it was stopped.

The patient is a middle-aged African American woman who for years required multiple pain pills every day to tolerate the pain of her sickle cell disease. Since beginning GenoMed's trial on Dec. 22, 2005, she experienced no pain until her trial medication ran out on February 6, 2006. Said her physician, who is lead author on the case report, 'Prior to this experiment, for over two years, there has not been more than a day, at least during the winter months, when she has not required some Vicodin.'

Her pain ceased within a few days of resuming GenoMed's treatment in February. In June, her physician intentionally stopped GenoMed's treatment. Off GenoMed's treatment, the patient's pain recurred within a week. When she again resumed GenoMed's treatment, her pain again stopped within a few days. She has been pain-free on GenoMed's treatment for three months now, since June.

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, 'Although only a single patient, she satisfied Koch's postulates, which constitute a rigorous clinical test. As long as the patient was using our treatment, her pain was gone. On two occasions, one accidental and one deliberate, our treatment was stopped. On both occasions her pain recurred promptly, only to disappear quickly after treatment was resumed. It doesn't get much more convincing than this.'

Added Dr. Moskowitz, 'Ever since Max Perutz showed the molecular defect in sickle cell hemoglobin in 1946, for which he won the Nobel Prize, sickle cell disease has been a sober reminder that knowing the molecular cause of a disease is still a far cry from curing it.'

Dr. Moskowitz ended by saying, 'We're eager to acquire more sickle cell patients to see if what has cured this patient's pain will work for every patient. It's fitting that our potential cure comes during America's Sickle Cell Awareness and Pain Awareness Month.'

Share RecommendKeepReplyMark as Last Read


From: jmhollen10/10/2006 9:32:22 AM
   of 347
 
Nature Medicine Articles Support GenoMed's Pending Patent on Bird Flu

Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com


ST. LOUIS—October 10, 2006—GenoMed™ (OTC Pink Sheets GMED), the Next Generation Disease Management company whose business is public health™, announced today that its approach to avian influenza ("bird flu") is now supported by the prestigious journal Nature Medicine.

Click here for Nature Medicine article of September 10, 2006 nature.com
Click here for Nature Medicine article of September 8, 2006 nature.com

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "It has taken the virology community a long time to recognize the lethality of high cytokine levels. We realized it four years ago. Two years ago, we published that our anti-inflammatory approach works for another lethal viral disease, West Nile virus encephalitis."

Dr. Moskowitz continued, "Unfortunately, the current Nature Medicine articles still point to the danger of a high viral load and call for anti-viral drugs. We believe that cytokines kill the patient, not the virus. GenoMed's approach is to convert patients to asymptomatic viral shedders, which is what happens naturally whenever a patient recovers from any viral illness. Our approach should make antiviral drugs unnecessary for the general population. For this reason GenoMed's general viral antidote was included in BioShield II (Section 2151)"

Added Dr. Moskowitz, "At this point, as with the rest of our treatments (Daily Newstown article), the crucial element missing is public awareness. We're reminded every day that if people had only known about us earlier, we could have saved their lives."

About GenoMed

GenoMed owns "use" patents (which are pending) for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure, including avian influenza. GenoMed estimates that it can already save 25% of healthcare costs and extend life by 5 years. The company is trying to get the world to realize this sooner rather than later.

.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: jmhollen who wrote (316)10/12/2006 2:58:31 PM
From: Tadsamillionaire
   of 347
 
Moskowitz needs a bigger drum! I realize he is the company, but this stuff works!

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Tadsamillionaire who wrote (317)10/13/2006 9:53:26 PM
From: jmhollen
   of 347
 
10-4.

Somebody in the AMA 'good ol' boys' network must really have it in for him, but eventually the 'cures' will outweigh the averice.

John :-)

.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: jmhollen who wrote (318)11/5/2006 1:36:11 PM
From: Tadsamillionaire
   of 347
 
Annals Publishes GenoMed's Approach to Avian Influenza
GenoMed(TM) (OTC Pink Sheets:GMED), the Next Generation Disease Management company whose business is public health(TM), announced today that its approach to avian influenza ("bird flu") has been published by the prestigious journal Annals of Internal Medicine.
October 24, 2006 - 10:12 AM EST
(http://www.annals.org/cgi/eletters/145/8/631#3964).

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "GenoMed is honored to have created a debate within the virology community about whether it's the viral load or the 'cytokine storm' which kills a patient with a lethal viral disease like avian influenza. Three years ago we applied for a patent saying that the 'cytokine storm' alone was lethal, and that the viral load could essentially be ignored. Two years ago, we published that our purely anti-inflammatory approach appears to work for another lethal viral disease, West Nile virus encephalitis."

Dr. Moskowitz continued, "We're eager to keep testing this hypothesis. If we're right, it will transform the way viral diseases are treated in the general population."

Added Dr. Moskowitz, "At this point, as with the rest of our treatments, the only element missing is public awareness. We're reminded every day that if people with viral disease, high blood pressure, diabetes, or emphysema only knew about us, we might be able to help save their lives."

About GenoMed

GenoMed owns "use" patents (which are pending) for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure, including avian influenza. GenoMed estimates that it can already save 10% of healthcare costs and extend life by several years. The company is currently trying to publicize its intellectual property, since having cures is useless if nobody knows about them.

Share RecommendKeepReplyMark as Last Read


From: Gary Mohilner11/29/2006 2:05:21 AM
   of 347
 
I'm no expert, but does the information in the following post agree with what Dr. M has been saying for some time.

Message 23051621

I wonder if he knows about this.

Gary

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Gary Mohilner who wrote (320)12/1/2006 9:15:45 PM
From: Tadsamillionaire
   of 347
 
Probably Not! EOM.

Share RecommendKeepReplyMark as Last Read


From: Tadsamillionaire12/12/2006 12:43:06 PM
   of 347
 
Philadelphia Group Confirms GenoMed's Approach to Pancreatic Cancer
GenoMed(TM) (Pink Sheets:GMED), the Next Generation Disease Management company whose business is public health(TM), announced today that its published approach to cancer has recently received support from a group at Thomas Jefferson University in Philadelphia.

Dr. Hwyda Arafat at the Kimmel Cancer Center at Thomas Jefferson University recently showed that angiotensin I-converting enzyme (ACE) was active in tumors from patients with pancreatic cancer, and that ACE inhibitors and angiotensin II receptor blockers (ARBs) blocked the production of a potent angiogenesis factor called VEGF in pancreatic cancer cell lines. She suggested that ACE inhibitors and ARBs might be useful in treating pancreatic cancer patients.

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Our work, published four years ago, demonstrated that ACE inhibitors and ARBs may work against all but a few cancers. In fact, two years ago we published a case report of a woman with stage IV unresectable pancreatic cancer who lived an extra 14 months using our approach."

Added Dr. Moskowitz, "We're delighted for others to confirm our work again, but if people with cancer, sickle cell disease, viral disease, high blood pressure, diabetes, kidney failure, or emphysema only knew about us, we might be able to help save their lives. At this point, as with the rest of our treatments, the only element missing is public awareness."

About GenoMed

GenoMed owns "use" patents (which are pending) for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure. GenoMed estimates that it can already save 10% of healthcare costs and extend life by several years. The company is currently trying to publicize its intellectual property, since having cures is useless if nobody knows about them.

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10